Lorenzo C. Pescatori
Vania Tacher
Hicham Kobeiter1,2- 1Assistance Publique - Hôpitaux de Paris (AP-HP), Service d'Imagerie Médicale, CHU Henri Mondor, Créteil, France
- 2Université Paris-Est Créteil (UPEC), Créteil, France
- 3Unité INSERM U955 #18, IMRB, Créteil, France
Endovascular approach is the first-choice treatment in patients suffering from aortoiliac occlusions. Nevertheless, standard endoluminal revascularization fails in treating occlusions in about 20% (1) of cases. Thus, subintimal revascularization can be a solution, but it fails in 25% (2) of cases as well. In the last decades, different devices have been created, in order to ease the cross back into the true lumen, when standard subintimal revascularization does not work or risks to occlude important collateral vessels. Herein, we revise the currently available re-entry devices and their application in the aortoiliac occlusive pathology.
Introduction
Aortoiliac disease is a major cause of claudication and/or critical limb ischemia, with a prevalence up to 10% in the general population, increasing up to 20% in patients aged over 70 (1).
In 2007, the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) stratified aortoiliac lesions considering length, grade of occlusion, and position and suggested endovascular (EV) approach for lesions classified TASC A and B and open surgery (OS) for lesions TASC C and D, including chronic total occlusions (CTOs) (3).
CTOs of the aortoiliac tract (AT) are challenging situations and they account for almost 35% of iliac interventions (4). In this setting, the patency rate of iliofemoral bypass can reach over 90% at 5 years, while EV treatment has a patency rate of 72% at 4 years (5).
Nevertheless, OS is associated with higher per-surgical complications and mortality than the EV technique (1). Thus, several EV options have been developed to treat even high-grade lesions, especially in elderly and fragile patients.
In the past years, EV management of CTOs was limited by the impossibility to cross highly calcified vascular segments or by the failure of simple percutaneous transcatheter angioplasties (PTAs). Then, stents able to fix failed PTAs have been commercialized, and percutaneous intentional extraluminal revascularization (PIER) has been described (6) as an ancillary technique, to cross CTOs.
Thus, nowadays, the main cause of technical failure is the inability to re-enter the true lumen (TL) beyond an occluded vascular segment (7), but different devices have been developed to overcome this problem as well.
This review aims to describe different re-entry devices (REDs) developed to increase the success in crossing CTOs of the AT that, otherwise, should be treated surgically or not treated at all.
Devices and Utilization
Pioneer Catheter
The first RED was commercialized in 2002, named CrossPoint TransAccess Catheter (TransSonic Systems, Inc., Ithaca, NY) (8) and then Pioneer catheter, after being acquired by Medtronic, Inc. (Santa Rosa, CA).
It consists of a monorail double-lumen catheter, integrated with an intravascular ultrasound (IVUS) array, transducing at 20 MHz [Volcano In-vision Gold IVUS console (Volcano, San Diego, CA)] and equipped with a curved needle allowing for passage of a 0.014″ non-hydrophilic guidewire.
Once the 0.035″ guidewire penetrates the subintimal space, it is exchanged for a 0.014″ guidewire and the Pioneer can be charged on it.
Once the catheter is in place, the IVUS system is activated to detect the position of the TL and the quality of the blood flow, through a color-flow mode (ChromaFlo feature), in order to choose the best area to cross back the intimal layer.
Then, the operator turns the handlebar at the bottom of the catheter to push out the needle, which is located 7 mm below the IVUS array, in order to perforate the intimal layer and to pass the re-entry guidewire into the TL (Figure 1).
Figure 1. The Pioneer catheter (image courtesy of Philips®), consisting of a monorail double-lumen catheter, integrated with an intravascular ultrasound tip. The handlebar at the bottom of the catheter allows one to push out the lateral needle, located 7 mm below the IVUS array, aiming to perforate the intimal layer and to pass a 0.014″ guidewire into the true lumen.
As the trajectory of the needle cannot be modified, the system has to be rotated until the TL is visualized at 12 o'clock in the IVUS cross-sectional still frame, as the needle will come out on that side.
To guarantee a precise puncture of the intimal layer, the length of the needle can be modified through the handlebar of the catheter, with a range varying from 1 to 7 mm.
The first Pioneer device was a 7-F catheter, able to penetrate thick and calcified plaques, but the stiffness of the system made it hard to navigate through bifurcations and densely calcified femoral vessels.
Then, a 6 Fr version of the catheter was released, allowing an easier navigation through narrower vessels.
The tracking system and the high penetration capability of the catheter allows precise iliac or aortic recanalization, reducing the risk for multiple extravascular punctures in the retroperitoneal space (2).
Outback Catheter
The first Outback catheter was released in 2003 by LuMend (Redwood City, CA). It was in a 5 Fr angled catheter, integrated with a curved needle at its top. The needle could be advanced by pushing it from the bottom of the catheter, to penetrate the intimal layer and to pass a 0.014″ guidewire in the TL. The only way to orientate the puncture was by rotating the catheter and following the needle's direction on the fluoroscopy images (9).
Then, Cordis (Cordis Corporation, Bridgewater, NJ) purchased the device and released a second generation of 6 Fr monorail single-lumen catheters, called Outback LTD, adding a radiopaque marker to detect the position of the catheter on fluoroscopy.
The needle is placed 12 mm below the tip, while the marker surrounds the top of the catheter and it can have a “T” or an “L” shape on the fluoroscopy images, depending on whether the needle is frontal or lateral to the panel. Thus, by evaluating the aspect of the marker, the operator can detect the position of the needle in respect of the lumen of the artery (Figures 2, 3).
Figure 2. The Outback catheter (image courtesy of Cordis®), consisting of a lateral needle at the top (asterisk), that can be opened thanks to a knob located on the handlebar (arrow).
Figure 3. Outback LDT in the subintimal space of the abdominal aorta. The “L” marker is pointed at the true lumen of the aorta (arrow) with the 0.014″ guidewire passing through the needle inner lumen (asterisk).
Once the catheter is properly located, the guidewire has to be retracted about 5 cm, and then the needle can be opened (up to 10 mm) thanks to a knob located on the handlebar, and the same guidewire can be advanced in the inner lumen of the needle, to pass in the TL of the target artery.
Because the Outback catheter costs less than the Pioneer one (10), it is often the first choice when a RED is needed.
As for Pioneer, Outback LDT is hard to pass through highly calcified lesions or through tortuous aortic bifurcations. In those cases, the rotation of the RED can cause misplacement of the needle or mismatch between the needle's exit point and the radiological markers, with subsequent unsuccessful puncture (11).
Offroad Catheter
This device, purchased by Boston Scientific Corporation (Natick, MA) in 2011, gained FDA approval in 2013. It is composed of a needle hypotube and a tipless semicompliant 5.4-mm balloon catheter, compatible with a 0.035″ guidewire.
Once the guidewire is in the subintimal space, the catheter is inserted, and the balloon is inflated, when located beyond the distal part of the CTO.
Since the balloon has a conical shape, and the intima is softer than the media and adventitia, the inflation tends to deflect the balloon toward the intima. Then, the needle hypotube is advanced though the intimal layer and a 0.014″ guidewire is passed in the TL (Figure 4).
Figure 4. Offroad catheter (image courtesy of Boston Scientific®), composed of an inner lumen, compatible with a 0.035″ guidewire, and a tipless semicompliant balloon catheter with a conical shape (asterisk).
The inflation system and the shape of the balloon allow one to direct the puncture at the middle of the distal TL and reduce the maneuvers needed to trace the position of the catheter. Then, it exists in two different working lengths (70 and 100 cm), allowing anterograde and retrograde approach to the lesion.
The system is softer than the others previously described and can be helpful when dealing with complex anatomies, but it can fail to penetrate severe calcifications. This is probably the main limitation to its use in the AT.
Some studies came out regarding Offroad utilization in the lower limb territory, but only few cases regarding the AT have been described so far (12).
Enteer Catheter
The device has been released in 2012 by Covidien (Mansfield, MA), and it is mainly used to perform coronary angioplasties (13). A flat balloon is integrated at the top of the catheter. Once the balloon is inflated in the subintimal plane, it orientates with the flat side at the interface between the intimal layer and the adventitia. Thus, a stiff 0.014″ guidewire can be inserted through a side-hole placed on the flat part of the balloon to reach the TL (Figure 5).
Figure 5. Enteer catheter [image courtesy of Whitlow et al. (13)] has a flat balloon (10 mm long, 2.5 mm wide) at its top provided with a side hole allowing the passage for a 0.014″ guidewire, directed through the intimal layer.
The catheter is designed to navigate small vessels, and some series reported good results in the coronary and limb territory but, to our best knowledge, no studies on the aortoiliac territory have been performed.
Discussion
Traditional intraluminal revascularization (IR) is often considered the best option when dealing with stenoses or occlusions of the AT, as it is the most anatomical approach (14). Nevertheless, IR fails in about 20% of cases, depending on the length and strength of the target lesions (15). In those cases, PIER can be a good alternative. The technique was firstly described by Bolia et al. widening the EV approach to patients that could be only treated with OS until then (6).
Traditional PIER, performed with a hydrophilic guidewire and a support catheter, can cross the lesion by dissecting the subintimal space, passing through the occluded area and crossing back distally in the TL (14). However, it fails in revascularizing long or highly calcified iliac CTOs in about 20–25% of cases (2, 16), because of failure to re-enter the TL (17–20) or because the dissection occludes vessels that should be spared to keep patency of the collateral network (6, 18, 21, 22).
RED allows to cross back on a given point of the TL, in short time and without extension of the dissected segment (18, 23), increasing the chance of success as well as reducing procedural time, radiation exposure, and risk of complication related to extensive dissection (7, 24).
The approach at our Institution is to try at first for a traditional PIER and, when unsuccessful attempts last for 10 to 20 min, a RED is inserted and, as reported in literature, it usually solves the cross back in <10 min (7, 25). Our experience in the aortoiliac district is limited to the Outback catheter, even though the Pioneer catheter could be a viable alternative while, in the opinion of the authors, the Enteer and Offroad catheters should be limited to the lower-limb territory, because of their characteristics and size (Figure 6).
Figure 6. Anatomical diagram of preferred territory of intervention for each re-entry catheter.
Considering the stiffness of the system, the preferred approach is the retrograde homolateral one even though anterograde contralateral approach has been described (2) but, as already said, tortuous bifurcations can misalign inner lumen and markers of the catheter, with subsequent unsuccessful performance (11).
Recently, Kokkinidis et al. (2) published a systematic review of the literature, concerning 1002 patients (and 1112 lesions) who benefit from a PIER of the AT with or without RED. Specifically, 22% of lesions were treated with RED and, out of the eight studies providing the information, RED was used as a first option (without previously attempting traditional PIER) in 50% of papers. In fact, thanks to the possibility to precisely predict the landing zone of the cross back, RED can avoid risky maneuvers that could damage the ostium of important collateral arteries such as hypogastric, sacral, or lumbar ones. However, considering the whole populations, success rate was 89 and 85% after traditional and RED PIER, respectively, while considering only papers that reported the success rate of PIER with RED after failed traditional PIER, it was 100% in four cases and 91% in the last one. The most frequent reason of a failed cross back with RED is the presence of highly calcified landing zones that do not allow the needle passage or do prevent proper visualization of the TL through the IVUS images (2).
In the same review, complication rate was 6.9% in the RED group and 6.7% in the traditional PIER group (2), and this is an encouraging result, considering that patients who benefit from RED are usually burdened with more severe disease. Moreover, when details were given, perforations and embolization were more frequent during traditional PIER, confirming that the tracking systems of REDs reduce the risk of untargeted punctures (2).
In 2018, Kokkinidis et al. (26) also published the first paper comparing long-term outcomes after PIER of CTOs of the AT with or without RED and they found non-significant differences among the two groups, as target lesion revascularization rate at 1 and 5 years was 11 and 29% with RED and 9 and 29% with traditional PIER, with a post-angioplasty stenting rate of 82% after RED and 87% after traditional PIER.
The main limitation of REDs is their cost, that is, $1800 and $3100 for Outback LTD and Pioneer, respectively (10). A study carried out on the US market found that, even considering the secondary medical expenses of an unsuccessful revascularization, the Outback catheter increases the cost of the procedure for a mean of $400 (27).
In conclusion, the available literature regarding REDs is encouraging and shows good technical success, allowing access to EV therapies also to those patients suffering from severe vascular diseases that, for decades, were not even imaginable to treat with non-invasive approaches.
Author Contributions
HK conceived the review. LP wrote the manuscript. HK, VT, and LP contributed to the discussion.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Groot Jebbink E, Holewijn S, Slump CH, Lardenoije J-W, Reijnen MMPJ. Systematic review of results of kissing stents in the treatment of aortoiliac occlusive disease. Ann Vasc Surg. (2017) 42:328–36. doi: 10.1016/j.avsg.2017.01.009
2. Kokkinidis DG, Katsaros I, Jonnalagadda AK, Papanastasiou CA, Katamreddy A, Schizas D, et al. Use, safety and effectiveness of subintimal angioplasty and re-entry devices for the treatment of iliac artery chronic total occlusions: a systematic review of 30 studies and 1112 lesions. Cardiovasc Revasc Med. (2019) 21:334–41. doi: 10.1016/j.carrev.2019.05.022
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. (2007) 45(Suppl S):S5–67. doi: 10.1016/j.jvs.2006.12.037
4. Bjorck M, Troeng T, Bergqvist D. Risk factors for intestinal ischaemia after aortoiliac surgery: a combined cohort and case-control study of 2824 operations. Eur J Vasc Endovasc Surg. (1997) 13:531–9. doi: 10.1016/S1078-5884(97)80061-5
5. Minko P, Katoh M, Opitz A, Jäger S, Bücker A. Subintimale Revaskularisation von chronischen Iliakalverschlüssen mithilfe eines Reentry-Katheters. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgeb Verfahren. (2011) 183:549–53. doi: 10.1055/s-0031-1273345
6. Bolia A, Miles KA, Brennan J, Bell PRF. Percutaneous transluminal angioplasty of occlusions of the femoral and popliteal arteries by subintimal dissection. Cardiovasc Intervent Radiol. (1990) 13:357–63. doi: 10.1007/BF02578675
7. Jacobs DL, Motaganahalli RL, Cox DE, Wittgen CM, Peterson GJ. True lumen re-entry devices facilitate subintimal angioplasty and stenting of total chronic occlusions: initial report. J Vasc Surg. (2006) 43:1291–6. doi: 10.1016/j.jvs.2006.02.051
8. Saketkhoo RR, Razavi MK, Padidar A, Kee ST, Sze DY, Dake MD. Percutaneous bypass: subintimal recanalization of peripheral occlusive disease with IVUS guided luminal re-entry. Tech Vasc Interv Radiol. (2004) 7:23–7. doi: 10.1053/j.tvir.2004.01.006
9. Hausegger KA, Georgieva B, Portugaller H, Tauss J, Stark G. The outback catheter: a new device for true lumen re-entry after dissection during recanalization of arterial occlusions. Cardiovasc Intervent Radiol. (204) 27:26–30. doi: 10.1007/s00270-003-0025-x
10. Re-Entry Devices in the Treatment of Peripheral Chronic Occlusions. Available online at: https://www.ncbi.nlm.nih.gov/pubmed/?term=.+Re-Entry+Devices+in+the+Treatment+of+Peripheral+Chronic+Occlusions+-+smith (accessed January 27, 2020).
11. Raskin D, Khaitovich B, Balan S, Silverberg D, Halak M, Rimon U. The Aortic bifurcation angle as a factor in application of the outback for femoropopliteal lesions in ipsilateral versus contralateral approaches. Cardiovasc Intervent Radiol. (2018) 41:37–42. doi: 10.1007/s00270-017-1761-7
12. Langhoff R, Stumpe S, Treitl M, Schulte KL. Successful revascularization of chronic total occlusion of lower extremity arteries: a wire only and bail out use of re-entry device approach. J Cardiovasc Surg. (2013) 54:553–9.
13. Whitlow PL, Lombardi WL, Araya M, Michael Wyman R, Torres H, Dauvergne C, et al. Initial experience with a dedicated coronary re-entry device for revascularization of chronic total occlusions. Catheter Cardiovasc Interv. (2012) 80:807–13. doi: 10.1002/ccd.23417
14. Kokkinidis DG, Alvandi B, Hossain P, Foley TR, Kielhorn CE, Singh GD, et al. Midterm outcomes after endovascular intervention for occluded vs stenosed external iliac arteries. J Endovasc Ther. (2018) 25:183–91. doi: 10.1177/1526602818761664
15. Yilmaz S, Sindel T, Lüleci E. Subintimal versus intraluminal recanalization of chronic iliac occlusions. J Endovasc Ther. (2004) 11:107–18. doi: 10.1583/03-1077.1
16. Vuruskan E, Saracoglu E. Procedural and early outcomes of two re-entry devices for subintimal recanalization of aortoiliac and femoropopliteal chronic total occlusions. Korean Circ J. (2017) 47:89–96. doi: 10.4070/kcj.2016.0310
17. London NJ, Srinivasan R, Naylor AR, Hartshorne T, Ratliff DA, Bell PR, et al. Subintimal angioplasty of femoropopliteal artery occlusions: the long-term results. Eur J Vasc Surg. (1994) 8:148–55. doi: 10.1016/S0950-821X(05)80450-5
18. Lipsitz EC, Ohki T, Veith FJ, Suggs WD, Wain RA, Cynamon J, et al. Does subintimal angioplasty have a role in the treatment of severe lower extremity ischemia? J Vasc Surg. (2003) 37:386–91. doi: 10.1067/mva.2003.20
19. Met R, Van Lienden KP, Koelemay MJW, Bipat S, Legemate DA, Reekers JA. Subintimal angioplasty for peripheral arterial occlusive disease: a systematic review. Cardiovasc Intervent Radiol. (2008) 31:687–97. doi: 10.1007/s00270-008-9331-7
20. Scott EC, Biuckians A, Light RE, Burgess J, Meier GH, Panneton JM. Subintimal angioplasty: our experience in the treatment of 506 infrainguinal arterial occlusions. J Vasc Surg. (2008) 48:878–84. doi: 10.1016/j.jvs.2008.05.037
21. Ko Y-G, Shin S, Kim KJ, Kim J-S, Hong M-K, Jang Y, et al. Efficacy of stent-supported subintimal angioplasty in the treatment of long iliac artery occlusions. J Vasc Surg. (2011) 54:116–22. doi: 10.1016/j.jvs.2010.11.127
22. Antoniou GA, Chalmers N, Georgiadis GS, Lazarides MK, Antoniou SA, Serracino-Inglott F, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg. (2013) 57:242–53. doi: 10.1016/j.jvs.2012.07.038
23. Chen BL, Holt HR, Day JD, Stout CL, Stokes GK, Panneton JM. Subintimal angioplasty of chronic total occlusion in iliac arteries: a safe and durable option. J Vasc Surg. (2011) 53:367–73. doi: 10.1016/j.jvs.2010.08.073
24. Kickuth R, Ludwig KC, Do D-D, Husmann M, Baumgartner I, Triller J. Guidance of interventions in subintimal recanalization and fenestration of dissection membranes using a novel dual-lumen intravascular ultrasound catheter. Rofo. (2006) 178:898–905. doi: 10.1055/s-2006-926934
25. Krishnamurthy VN, Eliason JL, Henke PK, Rectenwald JE. Intravascular ultrasound-guided true lumen reentry device for recanalization of unilateral chronic total occlusion of iliac arteries: technique and follow-up. Ann Vasc Surg. (2010) 24:487–97. doi: 10.1016/j.avsg.2009.12.002
26. Kokkinidis DG, Alvandi B, Cotter R, Hossain P, Foley TR, Singh GD, et al. Long-term outcomes after re-entry device use for recanalization of common iliac artery chronic total occlusions. Catheter Cardiovasc Interv. (2018) 92:526–32. doi: 10.1002/ccd.27583
27. Banerjee S, Jeon-Slaughter H, Tsai S, Mohammad A, Foteh M, Abu-Fadel M, et al. Comparative assessment of procedure cost and outcomes between guidewire and crossing device strategies to cross peripheral artery chronic total occlusions. JACC Cardiovasc Interv. (2016) 9:2243–52. doi: 10.1016/j.jcin.2016.08.010
Keywords: re-entry catheter, aortoiliac occlusion, subintimal recanalization, chronic total occlusion, extraluminal
Citation: Pescatori LC, Tacher V and Kobeiter H (2020) The Use of Re-entry Devices in Aortoiliac Occlusive Disease. Front. Cardiovasc. Med. 7:144. doi: 10.3389/fcvm.2020.00144
Received: 14 April 2020; Accepted: 06 July 2020;
Published: 25 August 2020.
Edited by:
Romaric Loffroy, Centre Hospitalier Regional Universitaire De Dijon, FranceReviewed by:
Shinichi Ota, Shiga University of Medical Science, JapanPramod P. Rao, Hôpital Pasteur, France
Copyright © 2020 Pescatori, Tacher and Kobeiter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lorenzo C. Pescatori, lorenzo.pescatori@aphp.fr